Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 298 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo inhaler Clear all

Conditions: Cancer
Interventions: Ginger aromatherapy, Orange aromatherapy, Lavender aromatherapy, Jojoba aromatherapy; Other
Lead sponsor: University of Rochester; Other
Eligibility: 8 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GFF MDI (PT003), GP MDI (PT001), FF MDI (PT005), Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 113
States / cities: Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: LTI-03, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Rein Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more

Conditions: Status Asthmaticus
Interventions: Montelukast Oral Granules, Albuterol, Corticosteroid; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Exercise Induced Bronchospasm
Interventions: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler; Combination Product
Lead sponsor: Bond Avillion 2 Development LP; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 3 more

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, Placebo only; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 1,493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 20 more

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 10
States / cities: Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more

Conditions: Asthma
Interventions: Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 9 Years
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 18
States / cities: Little Rock, Arkansas • Huntington Beach, California • Homestead, Florida + 12 more

Conditions: Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions: Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 221
States / cities: Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: JNJ 49095397, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Phoenix, Arizona • St Louis, Missouri • Chapel Hill, North Carolina + 3 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 87
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002, Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 9 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 74
States / cities: Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI) sensor device, Rescue medication; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 76 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 8 more

Conditions: Safety in Asthma Patients
Interventions: ASY202, Placebo; Combination Product
Lead sponsor: Aspeya, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Glendale, Arizona • Anaheim, California • San Antonio, Texas

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Asthma
Interventions: GP MDI, BFF MDI, Placebo MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Bakersfield, California • Lancaster, California • Long Beach, California + 12 more

Conditions: Nausea, Vomiting
Interventions: Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 75 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more

Search by objective public record fields.

Aromatherapy for Integrated Cancer Care

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Treating Exacerbations of Asthma With Oral Montelukast in Children

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Study of Mosliciguat in PH-ILD

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

12-week Efficacy of Indacaterol

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)